RE: The Presentation4 Dec 2023 12:39
'Then there is the multi million cost of an FDA application, which will need a funding partner too.'
It sounded to me as if GDR was going to qualify for either De novo or 510K routes. Both are much quicker than 9 - 12 months and also far, far cheaper. I'm happy to see both sides of the argument but to only point out the worst case scenario isn't entirely helpful.
IMHO Cheek has rolled the dice big time here. He needs to deliver some fairly spectacular news before Xmas and for that to budge the sp considerably higher EVEN THOUGH everyone knows that on the back of that he needs to do a fund raise. This is where his strategy doesn't quite add up to me. Regardless of good news landing now many if not all investors will hold fire because they know what's on the near horizon. Therefore Cheek has rather shot himself in the foot to deliver that fund raise at anything like a decent level...UNLESS the news really IS significant. Let's say we hear of 6 or 7 new NHS Trusts taking up AIHL testing, sales in the EU are under way AND one of the fast and cheap routes to FDA approval is confirmed, then I think the sp would rise no matter what fund raise is just around the corner.
Even if just AIHL is seeling in the UK, EU and US then the sp should be at a minimunm of 20p even without confirmed sales figures.
So, the ideal scenario is fab news is announced, sp rises to 15p+ and then a raise is done at between 10 and 12p and thereafter it soars to 40p+